SOURCE: IBF Conferences Inc.

October 26, 2006 12:56 ET

J. William Freytag, Ph.D., President & CEO of Myogen to Be Special Guest at 14th Annual Biotech Investing Conference

NEW YORK, NY -- (MARKET WIRE) -- October 26, 2006 --IBF Conferences, Inc. and SRI International today announced that J. William Freytag, Ph.D., President & CEO of Myogen, will be a special guest at the 14th Annual Biotech Investing Conference held at SRI International at Menlo Park, CA.

Mr. Freytag will be the special guest during the fireside chat to be held on November 8th at 4:30 PM. Camille Samuels, Managing Director of Versant Ventures, will be conducting the interview and said of Mr. Freytag, "Bill has been at the helm of Myogen since 1998 -- and successfully led the company through many of biotech's toughest challenges including fundraising in difficult times and managing through a product failure. Now, Bill is preparing to transition Myogen to its acquirer, Gilead, for $2.5 Billion! Every student of biotechnology can learn from Bill's experiences and thoughtful approach."

The 14th Annual Biotech Investing Conference, November 8, 2006, being held at SRI International, is a program to keep venture investors informed of emerging trends in the biotech sector, as well as investing strategies and collaborative business opportunities. In addition, the conference will also provide big pharma's perspective on rebuilding the pipeline and a look at how foundations are becoming a tool to fund early-stage research. There will also be an NVCA hosted pre conference reception held on November 7th -- CELEBRATE THE EMERGENCE OF A NEW CLASS OF BIOTECH INVESTORS -- which is free for all to attend.

Join leading firms such as New Enterprise Associates, Versant Ventures, CMEA Ventures and Amgen Ventures as well as foundations such as The Michael J. Fox Foundation for Parkinson's Research and Cystic Fibrosis Foundation Therapeutics, along with the FDA to discuss the following topics:

--  TRENDS IN EARLY, MID AND LATER STAGE BIOMEDICAL INVESTING
--  PRIVATE EQUITY INVESTOR & HEDGE FUND APPETITE FOR BIO COMPANIES
--  FOUNDATIONS "BRIDGE THE GAP": PARTNERING WITH VCS AND ENTREPRENEURS
    TO FUND EARLY STAGE BIOTECH
--  BIG PHARMA SPEAKS OUT ON THEIR APPROACH TO FILLING THEIR PIPELINE
--  FDA ACCELERATED DRUG DEVELOPMENT PROGRAMS:
      - KEY ISSUES IN ADDRESSING ORPHAN MARKETS
      - HOW THE FDA IS SUPPORTING ACCELERATED DRUG DEVELOPMENT
--  EXIT OUTLOOK
This year's conference sponsors include: SRI International, ABD Insurance & Financial Services, GE Healthcare Financial Services Life Science Finance, O'Melveny & Myers LLP and Charter Life Sciences.